Macular Degeneration News and Research

Latest Macular Degeneration News and Research

EyePromise® eye vitamins offers education guide to promote awareness on AMD

Due to the aging Baby Boomer population, AMD, or Age-related Macular Degeneration, is expected to double by the year 2020.

4 Feb 2015

New test can help measure vital aspects of retinal health

New research published in the February 2015 issue of The FASEB Journal details a test developed using mice that can help measure two important aspects of retinal health--the function of retinal blood vessels and light-detecting cells. This approach opens new possibilities for understanding the molecular changes that occur in retinal disease and for evaluating the benefits of treatment early in the course of disease.

3 Feb 2015

Reversing effects of early stage age-related macular degeneration may be possible

A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.

3 Feb 2015

Researchers identify molecular mechanisms that can prevent blindness, promote recovery from stroke

Research led by Nicolas Bazan, MD, PhD, Boyd Professor, Ernest C. and Yvette C. Villere Chair of Retinal Degeneration Research, and Director of the Neuroscience Center of Excellence at LSU Health New Orleans, has discovered gene interactions that determine whether cells live or die in such conditions as age-related macular degeneration and ischemic stroke.

31 Jan 2015

Abbott's new TECNIS Multifocal IOLs now available in the U.S. for people with cataracts

Two new intraocular lenses (IOLs) that restore vision to people with cataracts are now available in the United States. The new TECNIS Multifocal IOLs, developed by Abbott, provide people with cataracts options to have a full range of near, intermediate and distance vision, while customizing their treatment based on their personal vision needs and lifestyle.

30 Jan 2015

Hutchinson-Gilford Progeria Syndrome can be compared to normal aging, say scientists

In a new research study, scientists from Vision Genomics, LLC, Insilico Medicine, Inc., and Howard University showed that Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) is comparable to normal aging with respect to cellular signaling pathways, and that HGPS truly recapitulates the normal aging process.

28 Jan 2015

Tackling preventable blindness: a House of Commons reception review

“Macular degeneration is not life threatening, but it is life changing,” these were the words of Michael Valenzia, of the Macular Society at the recent House of Commons Reception held by AMD Alliance International.

27 Jan 2015

Microscopic spheres of calcium phosphate linked to AMD development

Microscopic spheres of calcium phosphate have been linked to the development of age-related macular degeneration (AMD), a major cause of blindness, by UCL-led research.

21 Jan 2015

Tiny lumps of calcium phosphate may trigger age-related macular degeneration

New research from scientists at the University of Maryland School of Medicine has found that tiny lumps of calcium phosphate may be an important triggering factor for age-related macular degeneration (AMD), a degenerative eye disease that can cause severe vision loss and blindness.

20 Jan 2015

Iron accumulation in human tissues may contribute to the aging process

It's been known for decades that some metals, including iron, accumulate in human tissues during aging and that toxic levels of iron have been linked to neurologic diseases, such as Parkinson's. Common belief has held that iron accumulation happens as a result of the aging process.

17 Jan 2015

Carl Zeiss Meditec to invest in Oraya Therapy for treatment of wet AMD

Carl Zeiss Meditec AG and Oraya Therapeutics, Inc. jointly announced today that the companies have entered into a collaboration agreement under which Carl Zeiss Meditec will provide funding to Oraya over a period of up to two years for the implementation of Oraya’s growth strategy, and in turn receive rights in the company reaching up to a majority stake after two years.

8 Jan 2015

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth.

7 Jan 2015

Scientific collaboration reveals encouraging insight on AMD disease

Insilico Medicine along with scientists from Vision Genomics and Howard University shed light on AMD disease, introducing the opportunity for eventual diagnostic and treatment options.

12 Dec 2014

Exudation-free period key to cataract surgery success in AMD

Cataract surgery can benefit patients with exudative age-related macular degeneration previously treated with anti-vascular endothelial growth factors if they have been treated and are exudation-free for more than 12 months, study findings indicate.

11 Dec 2014

Optical coherence tomography methods comparable for AMD assessments

There is good accordance between spectral-domain and time-domain optical coherence tomography image assessments of eyes treated for neovascular age-related macular degeneration, show study findings.

11 Dec 2014

OCT enhances neovascular subtype detection in AMD

Researchers recommend the inclusion of optical coherence tomography anatomic classification with fluorescein angiography grading to identify initial neovascular lesion subtypes in newly diagnosed age-related macular degeneration.

11 Dec 2014

Breakthrough research could lead to prosthetic retinas for people suffering from retinal damage

Scientists have developed a new light-sensitive film that could one day form the basis of a prosthetic retina to help people suffering from retinal damage or degeneration. Hebrew University of Jerusalem researchers collaborated with colleagues from Tel Aviv University and Newcastle University in the research, which was published in the journal Nano Letters.

5 Dec 2014